OCTRIDE DEPOT 20 mg (Octreotide Vials) 20mg

Octreotide Depot 20 mg vials offer sustained-release somatostatin analog therapy for hormone-related conditions. Used under medical supervision, these vials provide extended-release octreotide for subcutaneous injection. Ideal for long-term symptom management in approved indications.

Strength

20mg

Manufacturer / TM Owner

Sun Pharmaceutical Ind Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Octreotide Depot 20 mg vials are prescribed to reduce symptoms associated with acromegaly and certain neuroendocrine tumors. They help control excessive hormone production like growth hormone and insulin. This medication is also used for managing carcinoid syndrome symptoms such as flushing and diarrhea. Patients may ask, 'what is octreotide 20 mg used for' to understand its role in hormone regulation.

Side Effects

Octreotide Depot 20 mg vials may help stabilize hormone levels and reduce associated symptoms over time. Common effects include improved comfort and fewer episodes of flushing or diarrhea in neuroendocrine conditions. Some users report reduced abdominal discomfort and improved quality of life during treatment.

Precautions & Warnings

Store Octreotide Depot 20 mg vials as directed, typically refrigerated until use. Protect from light and moisture. Always follow handling instructions provided with the product. Discard any unused portion after the recommended timeframe to ensure potency and safety.

Avoid Interactions

Octreotide may interact with medications that affect heart rhythm or blood sugar levels. Caution is advised when combining with drugs metabolized by CYP enzymes. Alcohol use may alter effectiveness or side effects. Always inform healthcare providers about all current medications before starting octreotide therapy.

References

Frequently Asked Questions

Octreotide 20 mg is used to manage symptoms of acromegaly, neuroendocrine tumors, and carcinoid syndrome by regulating hormone production.

Octreotide Depot 20 mg is typically administered as a deep subcutaneous injection by a healthcare professional every 4 weeks.

Common side effects may include gastrointestinal discomfort, headache, or injection site reactions; consult a healthcare provider for personalized advice.

Octreotide Depot 20 mg is often prescribed for long-term use to manage chronic conditions under medical supervision.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.